Miracle Leaf® Health Centers
Tirzepatide works differently from semaglutide at the receptor level, and that difference is the reason it has a page of its own rather than a line on our semaglutide page.
A dual-hormone mechanism, not just another GLP-1
Semaglutide activates a single hormone receptor, GLP-1. Tirzepatide activates two: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. This dual-agonist mechanism is the core scientific distinction between the two medications rather than a marketing detail.
Whether that difference matters for you is not something a page can answer. It depends on your health history, what you have already tried, and what the provider who evaluates you concludes.
Two brand names, two different approvals
Tirzepatide is sold under two brand names depending on what it is treating:
- Zepbound® is FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition.
- Mounjaro® is FDA-approved for type 2 diabetes.
Same active ingredient, different approved uses, in the same way Ozempic® and Wegovy® both contain semaglutide but carry different approvals. Mounjaro® is not approved for weight management, so any weight-related use of it would be off-label, which is worth understanding plainly before you decide anything.
As with semaglutide, approval attaches to a specific product rather than to the molecule. A product containing tirzepatide is not automatically covered by Zepbound®‘s approval. Ask the provider which product they are prescribing and what its approval status is.
What a provider evaluates
Miracle Leaf® does not conduct this evaluation. A licensed provider reviews your health history, current medications, and weight-related conditions, and determines whether tirzepatide is a reasonable option for you specifically, typically starting at a low dose and increasing every few weeks as tolerated.
What to expect
The most commonly reported side effects mirror those of other GLP-1 and dual-agonist medications: nausea, diarrhea, vomiting, and other gastrointestinal symptoms, most noticeable when starting or after a dose increase.
For what a specific medication costs and whether it is available to you, ask the licensed provider who conducts your evaluation. Pricing depends on the product prescribed and on the pharmacy that fills it, so a figure quoted here would not reliably describe what you are offered.
If you are weighing tirzepatide against other options, our semaglutide page covers the single-receptor medication, our oral semaglutide page covers the pill form, and our metformin page covers an older, non-injectable option some providers use instead of or alongside a GLP-1 or dual-agonist medication.
Sources
- FDA approval history for Zepbound® (November 2023) and Mounjaro® (May 2022), per public FDA and manufacturer approval records, for the approved indications above
- Heally’s published comparison of tirzepatide and semaglutide (getheally.com/patients/news/tirzepatide-vs-semaglutide), pulled 2026-07-23, for the dual-receptor mechanism described above